TOVX Insider Trading

Insider Ownership Percentage: 5.27%
Insider Buying (Last 12 Months): $16,380.00
Insider Selling (Last 12 Months): $0.00

Theriva Biologics Insider Trading History Chart

This chart shows the insider buying and selling history at Theriva Biologics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Theriva Biologics Share Price & Price History

Current Price: $0.48
Price Change: Price Increase of +0.03 (6.60%)
As of 03/27/2024 01:00 AM ET

This chart shows the closing price history over time for TOVX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Theriva Biologics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/6/2023Steven A ShallcrossCEOBuy26,000$0.63$16,380.00236,000View SEC Filing Icon  
2/10/2023Steven A ShallcrossCEOBuy25,000$1.04$26,000.00210,000View SEC Filing Icon  
2/2/2023Steven A ShallcrossCEOBuy25,000$0.94$23,500.00185,000View SEC Filing Icon  
1/25/2023Steven A ShallcrossCEOBuy25,000$0.87$21,750.00160,000View SEC Filing Icon  
1/20/2023Steven A ShallcrossCEOBuy25,000$0.75$18,750.00135,000View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Theriva Biologics (NYSEAMERICAN:TOVX)

6.17% of Theriva Biologics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at TOVX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Theriva Biologics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
3/11/2024Vanguard Group Inc.366,580$0.16M0.0%-28.5%2.151%Search for SEC Filing on Google Icon
2/15/2024Vanguard Group Inc.366,580$0.16M0.0%-28.5%2.151%Search for SEC Filing on Google Icon
2/15/2024Citadel Advisors LLC57,953$25K0.0%N/A0.340%Search for SEC Filing on Google Icon
5/16/2023Geode Capital Management LLC116,301$81K0.0%N/A0.769%Search for SEC Filing on Google Icon
5/12/2023BlackRock Inc.190,169$0.13M0.0%N/A1.258%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Theriva Biologics logo
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Read More on Theriva Biologics

Today's Range

Now: $0.48
Low: $0.46
High: $0.50

50 Day Range

MA: N/A

52 Week Range

Now: $0.48
Low: $0.20
High: $1.20

Volume

84,281 shs

Average Volume

181,694 shs

Market Capitalization

$8.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Who are the company insiders with the largest holdings of Theriva Biologics?

Theriva Biologics' top insider investors include:
  1. Steven A Shallcross (CEO)
Learn More about top insider investors at Theriva Biologics.

Who are the major institutional investors of Theriva Biologics?

Theriva Biologics' top institutional investors include:
  1. Vanguard Group Inc. — 2.15%
  2. Vanguard Group Inc. — 2.15%
  3. Citadel Advisors LLC — 0.34%
Learn More about top institutional investors of Theriva Biologics stock.

Which major investors are selling Theriva Biologics stock?

In the last quarter, TOVX stock was sold by these institutional investors:
  1. Vanguard Group Inc.
  2. Vanguard Group Inc.

Which major investors are buying Theriva Biologics stock?

In the previous quarter, TOVX stock was acquired by institutional investors including:
  1. Citadel Advisors LLC